Any toxicity starting during the first 28 days of treatment and requiring ‡14 days of treatment interruption Grade 3/4 neutropenia associated with fever >38.5°C (febrile neutropenia) Grade 3 anemia requiring a transfusion Any grade 4 hematological toxicity lasting >7 days Grade 4 thrombocytopenia or grade 3 or 4 thrombocytopenia associated with clinically significant bleeding Grade 3/4 nonhematological toxicity except for fatigue, attributable to any of the IPs and unresponsive to medical treatment within 4 days of onset Patients who experience grade ‡3 hyperbilirubinemia as an apparent DLT will be tested for conjugated bilirubin levels to rule out Gilbert syndrome or other conditions causing elevated levels principally of unconjugated bilirubin. If a phase I patient experienced a grade ‡3 hyperbilirubinemia due principally to unconjugated bilirubin, it was not to be defined as a DLT. The patient was to be removed from the study and the phase I patient was to be replaced. Grade ‡2 pneumonitis or interstitial lung disease AE, adverse event; DLT, dose-limiting toxicity.
